Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab Subcutaneous Induction Therapy in Moderately to Severely Active Crohn's Disease
2020-006165-11Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Guselkumab SC induction with Placebo SC induction (2 arms). Primary endpoint: Clinical remission (primary). Started Feb 2022; status: active.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2020-006165-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006165-11.